YAP/TAZ As Mechanobiological Signaling Pathway in Cardiovascular Physiological Regulation and Pathogenesis

Overview

Journal Mechanobiol Med

Date 2024 Sep 16

PMID 39281415

Authors

Rakibul Islam

Zhongkui Hong

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) persistently rank as a leading cause of premature death and illness worldwide. The Hippo signaling pathway, known for its highly conserved nature and integral role in regulating organ size, tissue homeostasis, and stem cell function, has been identified as a critical factor in the pathogenesis of CVDs. Recent findings underscore the significance of the Yes-associated protein (YAP) and the Transcriptional Coactivator with PDZ-binding motif (TAZ), collectively referred to as YAP/TAZ. These proteins play pivotal roles as downstream components of the Hippo pathway, in the regulation of cardiovascular development and homeostasis. YAP/TAZ can regulate various cellular processes such as cell proliferation, migration, differentiation, and apoptosis through their interactions with transcription factors, particularly those within the transcriptional enhancer associate domain (TEAD) family. The aim of this review is to provide a comprehensive overview of the current understanding of YAP/TAZ signaling in cardiovascular physiology and pathogenesis. We analyze the regulatory mechanisms of YAP/TAZ activation, explore their downstream effectors, and examine their association across numerous cardiovascular disorders, including myocardial hypertrophy, myocardial infarction, pulmonary hypertension, myocardial ischemia-reperfusion injury, atherosclerosis, angiogenesis, restenosis, and cardiac fibrosis. Furthermore, we investigate the potential therapeutic implications of targeting the YAP/TAZ pathway for the treatment of CVDs. Through this comprehensive review, our aim is to elucidate the current understanding of YAP/TAZ signaling in cardiovascular biology and underscore its potential implications for the diagnosis and therapeutic intervention of CVDs.

Citing Articles

Integrin and Its Associated Proteins as a Mediator for Mechano-Signal Transduction.

Katoh K Biomolecules. 2025; 15(2).

PMID: 40001469 PMC: 11853369. DOI: 10.3390/biom15020166.

References

Francisco J, Zhang Y, Jeong J, Mizushima W, Ikeda S, Ivessa A . Blockade of Fibroblast YAP Attenuates Cardiac Fibrosis and Dysfunction Through MRTF-A Inhibition. JACC Basic Transl Sci. 2020; 5(9):931-945. PMC: 7524792. DOI: 10.1016/j.jacbts.2020.07.009. View

Wang J, Liu S, Heallen T, Martin J . The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat Rev Cardiol. 2018; 15(11):672-684. DOI: 10.1038/s41569-018-0063-3. View

Simard C, Salle L, Rouet R, Guinamard R . Transient receptor potential melastatin 4 inhibitor 9-phenanthrol abolishes arrhythmias induced by hypoxia and re-oxygenation in mouse ventricle. Br J Pharmacol. 2011; 165(7):2354-64. PMC: 3413868. DOI: 10.1111/j.1476-5381.2011.01715.x. View

Mazimba S, Peterson P . Spotlight on Racial and Ethnic Disparities in Cardiovascular Disease. J Am Heart Assoc. 2021; 10(17):e023650. PMC: 8649227. DOI: 10.1161/JAHA.121.023650. View

Yu H, Yao Y, Bu F, Chen Y, Wu Y, Yang Y . Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells. Mol Immunol. 2019; 107:29-40. DOI: 10.1016/j.molimm.2019.01.004. View

Qi S, Zhu Y, Liu X, Li P, Wang Y, Zeng Y . WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Mol Cell. 2022; 82(10):1850-1864.e7. DOI: 10.1016/j.molcel.2022.03.027. View

Choi H, Zhang H, Park H, Choi K, Lee H, Agrawal V . Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat Commun. 2015; 6:6943. DOI: 10.1038/ncomms7943. View

Kim J, Kim Y, Kim J, Park D, Bae H, Lee D . YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J Clin Invest. 2017; 127(9):3441-3461. PMC: 5669570. DOI: 10.1172/JCI93825. View

Boucetta H, Zhang L, Sosnik A, He W . Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies. J Control Release. 2023; 365:236-258. DOI: 10.1016/j.jconrel.2023.11.012. View

10.

Yu B, Wang S . Angio-LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics. 2018; 8(13):3654-3675. PMC: 6037039. DOI: 10.7150/thno.26024. View

11.

Yu F, Zhao B, Panupinthu N, Jewell J, Lian I, Wang L . Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012; 150(4):780-91. PMC: 3433174. DOI: 10.1016/j.cell.2012.06.037. View

12.

Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W . Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res. 2016; 6(1):27-37. PMC: 4759394. View

13.

Zhang Q, Cao Y, Liu Y, Huang W, Ren J, Wang P . Shear stress inhibits cardiac microvascular endothelial cells apoptosis to protect against myocardial ischemia reperfusion injury via YAP/miR-206/PDCD4 signaling pathway. Biochem Pharmacol. 2021; 186:114466. DOI: 10.1016/j.bcp.2021.114466. View

14.

Byun J, Del Re D, Zhai P, Ikeda S, Shirakabe A, Mizushima W . Yes-associated protein (YAP) mediates adaptive cardiac hypertrophy in response to pressure overload. J Biol Chem. 2019; 294(10):3603-3617. PMC: 6416448. DOI: 10.1074/jbc.RA118.006123. View

15.

Song S, Xie M, Scott A, Jin J, Ma L, Dong X . A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther. 2017; 17(2):443-454. PMC: 5805581. DOI: 10.1158/1535-7163.MCT-17-0560. View

16.

Chen Y, Freedman N, Albert P, Huxley R, Shiels M, Withrow D . Association of Cardiovascular Disease With Premature Mortality in the United States. JAMA Cardiol. 2019; 4(12):1230-1238. PMC: 6802055. DOI: 10.1001/jamacardio.2019.3891. View

17.

Kim Y, Jho E . Regulation of the Hippo signaling pathway by ubiquitin modification. BMB Rep. 2018; 51(3):143-150. PMC: 5882221. DOI: 10.5483/bmbrep.2018.51.3.017. View

18.

Travers J, Kamal F, Robbins J, Yutzey K, Blaxall B . Cardiac Fibrosis: The Fibroblast Awakens. Circ Res. 2016; 118(6):1021-40. PMC: 4800485. DOI: 10.1161/CIRCRESAHA.115.306565. View

19.

Li T, Zeng Z . Adiponectin as a potential therapeutic target for the treatment of restenosis. Biomed Pharmacother. 2018; 101:798-804. DOI: 10.1016/j.biopha.2018.03.003. View

20.

Hemnes A, Humbert M . Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur Respir Rev. 2017; 26(146). PMC: 9488187. DOI: 10.1183/16000617.0093-2017. View